Service Optimisation of Prostate Cancer Therapy Pathway

This document is a report on the collaborative working project between Astellas Pharma Ltd and Portsmouth Hospitals University NHS Trust, focusing on the service optimisation of the Prostate Cancer Oral Systemic Anti-Cancer Therapy (SACT) pathway. The objective of the project is to conduct a service review of the Prostate Cancer Oral SACT Novel Hormone Therapy pathway to support the redesign of the cancer centre's service. It highlights the significant burden that new prostate cancer cases place on NHS capacity, with 48,500 patients diagnosed annually. The optimisation pathway aims to address inefficiencies and delays within the service, ultimately improving patient care and operational effectiveness. The report outlines potential benefits for patients, including reduced waiting times and increased satisfaction, while also addressing the NHS's need for improved service delivery and capacity. Astellas Pharma's commitment to supporting the NHS is emphasized, as well as the collaborative effort to enhance patient well-being through shared expertise.